This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
by Zacks Equity Research
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
SLNPositive Net Change AZNPositive Net Change NBIXPositive Net Change LQDAPositive Net Change
biotechs
Here's Why You Should Add INKT Stock to Your Portfolio Now
by Zacks Equity Research
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
INKTPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDAPositive Net Change
biotechs
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
by Sundeep Ganoria
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
ABBVPositive Net Change BIIBPositive Net Change JNJPositive Net Change
biotechs earnings medical pharmaceuticals
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
by Zacks Equity Research
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
AXSMPositive Net Change ALKSPositive Net Change JAZZPositive Net Change LQDAPositive Net Change
biotechs
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy Now
by Rimmi Singhi
ARCO, HALO, TX and ARRY screen as high-earnings-yield value picks as the Middle-East conflict sharpens stock selection.
HALOPositive Net Change TXPositive Net Change ARRYPositive Net Change ARCOPositive Net Change
alt-energy basic-materials biotechs medical restaurants retail
ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly
by Zacks Equity Research
AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.
LLYPositive Net Change ATAINegative Net Change LQDAPositive Net Change KNSAPositive Net Change
biotechs
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
by Ekta Bagri
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
DNLIPositive Net Change BIIBPositive Net Change RHHBYPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
by Zacks Equity Research
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
by Zacks Equity Research
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AZNPositive Net Change AMRNPositive Net Change LQDAPositive Net Change KNSAPositive Net Change
biotechs
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
by Zacks Equity Research
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
BIIBPositive Net Change LLYPositive Net Change IONSPositive Net Change
biotechs